Sotagliflozin is an orally administered dual SGLT1/2 inhibitor used alongside insulin to improve glycemic control in patients with type 1 diabetes mellitus. Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as canagliflozin and dapagliflozin, but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors.
- Mechanism
- Curator reviewed · 3 references
Sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2) are integral in the transport of glucose in the body. SGLT1 is the major transporter for glucose absorption in the gastrointestinal tract, while SGLT2 is the predominant transporter responsible for reabsorption of glucose in the glomerulus.
Sotagliflozin is a dual inhibitor of both SGLT1 and SGLT2. Inhibition of SGLT1 results in a delay in glucose absorption and a blunting of postprandial hyperglycemia, while inhibition of SGLT2 reduces renal reabsorption of filtered glucose, thereby increasing urinary glucose excretion.
- Primary indication
- In the US, sotagliflozin is indicated to reduce the risk of cardiovascular death and heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.Curator reviewed · 8 structured indications
- Formula / weight
- C21H25ClO5S · 424.94 g/mol (avg)
- First approval
- United States, 2023
- Code names
- LP-802034 · LX4211 · SAR439954
- Brand names
Resolves to
QKDRXGFQVGOQKS-CRSSMBPESA-NSMILESCCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1What you can answer from here — as of July 26, 2025
Which drugs share a target with Sotagliflozin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account